Loading
310.582.7900

Known Nationally for Excellence in Cancer Treatment, Research, and Education

The Angeles Clinic & Research Institute has established an international reputation for developing new cancer therapies, providing the best in experimental and traditional treatments, and expertly guiding and training the next generation of clinicians. We are committed to bringing innovative therapeutic options to all of our patients with cancer. Our board-certified fellowship-trained medical oncologists, surgeons, immunotherapists, pathologists, and dermatologists work closely together to advance cancer care. Click to read more.

Known Nationally for Excellence in Cancer Treatment, Research, and Education

The Angeles Clinic & Research Institute has established an international reputation for developing new cancer therapies, providing the best in experimental and traditional treatments, and expertly guiding and training the next generation of clinicians. We are committed to bringing innovative therapeutic options to all of our patients with cancer. Our board-certified fellowship-trained medical oncologists, surgeons, immunotherapists, pathologists, and dermatologists work closely together to advance cancer care. Click to read more.

Melanoma Center

Melanoma Clinical Trials

Experience is crucial when dealing with a rare aggressive cancer like melanoma. The Melanoma Center at The Angeles Clinic & Research Institute brings patients and expert physicians together in a clinical program offering state-of-the-art treatments along with access to the latest investigational agents. The Melanoma Trials Program at The Angeles Clinic leads the way with innovative immunotherapies and targetted therapies.

Melanoma Center

Melanoma Clinical Trials

Experience is crucial when dealing with a rare aggressive cancer like melanoma. The Melanoma Center at The Angeles Clinic & Research Institute brings patients and expert physicians together in a clinical program offering state-of-the-art treatments along with access to the latest investigational agents. The Melanoma Trials Program at The Angeles Clinic leads the way with innovative immunotherapies and targetted therapies.

The Angeles Clinic featured at ASCO 2013
Paradigm-shifting therapy for all solid tumors

Immunotherapy, specifically immune checkpoint inhibitors targeting the PD-1/PD-l1 pathway, took center stage at ASCO.  The Arie Crown theatre was the site of the Clinical Science Symposium in relation to these paradigm-shifting therapies where nearly 1,500 physicians, nurses, and collaborators were packed to hear about the therapies that would help not only melanoma patients but also those with lung, renal, ovarian and a host of other carcinomas.

The Angeles Clinic and Research Institute has been involved with PD-1/PD-L1 antibodies since their inception.  We were the first to have the drug deemed by the FDA to be a “breakthrough” therapy, Lambrolizumab(MK-3475), available for our patients.  This data was presented and simultaneously published in the New England Journal of Medicine (Hamid et al.).  Dr. Hamid then presented ground breaking data with anti-PDL1 antibody MPDL328A in melanoma. We are currently accruing to a study of this agent in combination with the BRAF inhibitor vemurafenib.

Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center presenting  data of the combination of the Anti-PD-1 antibody nivolumab in combination with Ipilimumab.  This was also simultaneously presented in the NEJM. Much has been made of the data presented which showed high reponse rates with PD-1 directed therapy.  We are proud to be the first site in the United States with the ability to offer this therapy (Ipilimumab and Nivolumab combination) to our patients through a major phase III collaborative effort.  (Wolchok et al)  The data is promising.  So too is the fact that we have these first-in-class paradigm-shifting therapeutics available for our patients at The Angeles Clinic and Research Institute.

Phase 1 Clincal Program expands at The Angeles Clinic

Success developing targeted therapies in oncology depends on the ability to identify new targets and develop agents that hit those targets in an efficient manner.  Major clinical advances in the care of common cancers have been made through participation of patients in Phase I clinical trials of agents that achieve this goal.  Predictive oncology biomarkers -  i.e., genes and genetic mutations, proteins and signalling pathways implicated in the proliferation and death of cancer cells - and their use to control tumor growth has been a major advancement allowing more efficacious therapy with decreased toxicity.  Our collaboration with pharmaceutical partners has been instrumental in bringing this care to our patients.  For more information; click here 

The Angeles Clinic Breast Cancer Advisor

It is an exciting time full of promise in breast cancer care.  Researchers and clinicians are continuing to move the field forward at a pace that is difficult to imagine, therefore a well educated public is also critical. It is for this reason that this newsletter has been created; dedicated to all who have experienced breast cancer and those who are simply interested in being informed. Click here

 

 

The Angeles Clinic featured at ASCO 2013
Paradigm-shifting therapy for all solid tumors

Immunotherapy, specifically immune checkpoint inhibitors targeting the PD-1/PD-l1 pathway, took center stage at ASCO.  The Arie Crown theatre was the site of the Clinical Science Symposium in relation to these paradigm-shifting therapies where nearly 1,500 physicians, nurses, and collaborators were packed to hear about the therapies that would help not only melanoma patients but also those with lung, renal, ovarian and a host of other carcinomas.

The Angeles Clinic and Research Institute has been involved with PD-1/PD-L1 antibodies since their inception.  We were the first to have the drug deemed by the FDA to be a “breakthrough” therapy, Lambrolizumab(MK-3475), available for our patients.  This data was presented and simultaneously published in the New England Journal of Medicine (Hamid et al.).  Dr. Hamid then presented ground breaking data with anti-PDL1 antibody MPDL328A in melanoma. We are currently accruing to a study of this agent in combination with the BRAF inhibitor vemurafenib.

Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center presenting  data of the combination of the Anti-PD-1 antibody nivolumab in combination with Ipilimumab.  This was also simultaneously presented in the NEJM. Much has been made of the data presented which showed high reponse rates with PD-1 directed therapy.  We are proud to be the first site in the United States with the ability to offer this therapy (Ipilimumab and Nivolumab combination) to our patients through a major phase III collaborative effort.  (Wolchok et al)  The data is promising.  So too is the fact that we have these first-in-class paradigm-shifting therapeutics available for our patients at The Angeles Clinic and Research Institute.

Phase 1 Clincal Program expands at The Angeles Clinic

Success developing targeted therapies in oncology depends on the ability to identify new targets and develop agents that hit those targets in an efficient manner.  Major clinical advances in the care of common cancers have been made through participation of patients in Phase I clinical trials of agents that achieve this goal.  Predictive oncology biomarkers -  i.e., genes and genetic mutations, proteins and signalling pathways implicated in the proliferation and death of cancer cells - and their use to control tumor growth has been a major advancement allowing more efficacious therapy with decreased toxicity.  Our collaboration with pharmaceutical partners has been instrumental in bringing this care to our patients.  For more information; click here 

The Angeles Clinic Breast Cancer Advisor

It is an exciting time full of promise in breast cancer care.  Researchers and clinicians are continuing to move the field forward at a pace that is difficult to imagine, therefore a well educated public is also critical. It is for this reason that this newsletter has been created; dedicated to all who have experienced breast cancer and those who are simply interested in being informed. Click here

 

 

View Current Newsletter
News and Events
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
Santa Monica Office
2001 Santa Monica Blvd, Suite 560W
Santa Monica, CA 90404
West Los Angeles Office
11818 Wilshire Blvd.
Los Angeles, CA 90025